# US 10,369,197 B2 · Use of CD24 for lowering low-density lipoprotein cholesterol levels > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,369,197 B2 - Document ID: US10369197B2 - Status: Granted - Kind: B2 - Application number: 15/572,330 - Filed: 2016-05-06 - Published: 2018-04-26 - Granted: 2019-08-06 - Earliest claimed: 2015-05-07 - Assignees: Oncoimmune, Inc. - Applicants: Oncolmmune, Inc. - Inventors: Yang Liu; Pan Zheng - Web page: https://patentgrep.com/patent/US10369197B2 ## CPC - A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants} - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere} - G01N 33/502: {for testing non-proliferative effects} - G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} - C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto - G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 - G01N 2800/323: Arteriosclerosis, Stenosis - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease. ## Claims ### Claim 1 A method of reducing low-density lipoprotein (LDL) cholesterol (LDL-C) levels in a human subject in need thereof, comprising administering a CD24 protein to the subject, wherein the CD24 protein comprises: (a) a mature human CD24 polypeptide comprising the sequence set forth in SEQ ID NO: 1 or 2; and, (b) a Fc region of a human IgG protein; and, wherein the Fc region is fused at the C-terminus of the CD24 protein. ### Claim 2 (depends on 1) The method of claim 1, wherein the subject has an elevated LDL-C. ### Claim 3 (depends on 2) The method of claim 2, wherein the subject has a LDL-C greater than or equal to 75 mg/dL. ### Claim 4 (depends on 2) The method of claim 2, wherein the subject has a LDL-C of greater than or equal to 70 mg/dL or 190 mg/dL. ### Claim 5 (depends on 1) The method of claim 1, wherein the subject has been previously treated with another LDL-C-lowering drug. ### Claim 6 (depends on 5) The method of claim 5, wherein the other LDL-C-lowering drug is a statin. ### Claim 7 (depends on 5) The method of claim 5, wherein the other LDL-C-lowering drug is an antagonist of PCSK9. ### Claim 8 (depends on 1) The method of claim 1, wherein the CD24 protein is soluble. ### Claim 9 (depends on 1) The method of claim 1, wherein the CD24 protein is glycosylated. ### Claim 10 (depends on 1) The method of claim 1, wherein the Fc region comprises a hinge region and CH2 and CH3 domains of the human IgG protein. ### Claim 11 (depends on 10) The method of claim 10, wherein the human IgG protein is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4. ### Claim 12 (depends on 11) The method of claim 11, wherein the CD24 protein comprises the sequence set forth in SEQ ID NO: 6, ii, or 12. ### Claim 13 (depends on 1) The method of claim 1, wherein the CD24 protein is produced using a eukaryotic protein expression system. ### Claim 14 (depends on 13) The method of claim 13, wherein the expression system comprises a vector contained in a Chinese Hamster Ovary cell line or a replication-defective retroviral vector. ### Claim 15 (depends on 14) The method of claim 14, wherein the replication-defective retroviral vector is stably integrated into the genome of a eukaryotic cell. ### Claim 16 A method of treating atherosclerosis in a human subject in need thereof, comprising administering a CD24 protein to the subject, wherein the amino acid sequence of the CD24 protein consists of SEQ ID NO: 6, 11, or 12. ### Claim 17 A method of lowering the risk of atherosclerotic cardiovascular disease in a human subject in need thereof, comprising administering a CD24 protein to the subject, wherein the amino acid sequence of the CD24 protein consists of SEQ ID NO: 6, 11, or 12. ### Claim 18 (depends on 12) The method of claim 12, wherein the amino acid sequence of the CD24 protein consists of the sequence set forth in SEQ ID NO: 6, ii or 12. ### Claim 19 (depends on 16) The method of claim 16, wherein the CD24 protein is soluble. ### Claim 20 (depends on 17) The method of claim 17, wherein the CD24 protein is soluble. ### Claim 21 A method of reducing LDL-C levels in a human subject in need thereof, comprising administering to the subject a CD24 protein consisting of the sequence set forth in SEQ ID NO: 6.